ACLX - NASDAQ

Arcellx, Inc.

ACLX·NASDAQ

$115.07

+0.0000%

HealthcareBiotechnology

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$6.73B

EPS-4.0700

P/E Ratio-28.27

Earnings Date05/14/2026

603.99M

Assets

-15%

3Y+92.0%

5Y+947.0%

10Y+3720.0%

201.64M

Total Liabilities

-21%

3Y+85.0%

5Y+2719.0%

10Y+11003.0%

402.35M

Total Equity

-12%

3Y+96.0%

5Y+696.0%

10Y+2782.0%

Arcellx, Inc. Funding & Solvency Profile

ACLX · NASDAQ

Current Assets

Cash & Cash Equivalents80.26M

Net Receivables3.60M

Inventory0.00

Other Current Assets8.25M

Total Current Assets462 M

Non-Current Assets

Property, Plant & Equipment0.00

Goodwill & Intangible Assets0.00

Long-Term Investments72.33M

Other Non-Current Assets69.47M

Total Non-Current Assets142 M

Total Assets

603.99M

Financial Health Analysis

Current Ratio

4.44x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.50x

Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.

Working Capital

358 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

77% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Arcellx, Inc. Balance Sheet

ACLX • NASDAQ

Arcellx, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	80.3M	105.7M	394.6M	64.2M	30.8M	46.6M	34.6M	14.5M
Short-Term Investments	370.1M	481.7M	307.4M	190.7M	73.8M	0.0	0.0	0.0
Cash & Short-Term Investments	450.3M	587.4M	702M	254.8M	104.6M	46.6M	34.6M	14.5M
Net Receivables	3.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Receivables	3.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	5.9M	6.8M	8.4M	6.1M	1.6M	2.9M	0.0
Other Current Assets	8.2M	6.1M	7.6M	3.7M	2M	1.2M	621K	99K
Total Current Assets	462.2M	599.3M	716.4M	266.9M	112.8M	49.4M	38.1M	14.6M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	0.0	70.2M	69.8M	39.9M	10.3M	4.9M	4.3M	817K
Long-Term Investments	72.3M	38.3M	27.2M	0.0	0.0	199K	0.0	0.0
Other Non-Current Assets	69.5M	3.5M	11.8M	7.1M	5.7M	3.2M	1.2M	366K
Total Non-Current Assets	141.8M	112M	108.8M	47M	16M	8.3M	5.5M	1.2M
Total Assets	604M	711.3M	825.1M	313.8M	128.8M	57.7M	43.6M	15.8M
LIABILITIES
CURRENT LIABILITIES
Total Payables	5.6M	23.3M	2.6M	9.1M	1.3M	504K	1.7M	1.1M
Accounts Payable	5.6M	2.1M	2.6M	9.1M	1.3M	504K	1.7M	1.1M
Other Payables	0.0	21.2M	0.0	0.0	0.0	0.0	0.0	-1.1M
Accrued Expenses	0.0	16.5M	4.6M	3.2M	7.9M	1.4M	239K	0.0
Short Term Debt	7.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	7.5M	46.8M	36M	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	59.1M	50.5M	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	91M	19M	13.7M	8.5M	5.6M	3.4M	1.1M	766K
Total Current Liabilities	104.2M	125.4M	118.2M	56.7M	14.8M	5.3M	3M	1.8M
NON-CURRENT LIABILITIES
Long Term Debt	44.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue (Non-Current)	53.1M	76M	170.7M	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	-44.3M	8.6M	0.0	0.0	235.5M	1.9M	73.3M	0.0
Total Non-Current Liabilities	97.4M	131.1M	221.5M	52.2M	235.5M	1.9M	73.3M	0.0
Capital Lease Obligations	44.3M	54.1M	97.6M	88.1M	0.0	0.0	0.0	0.0
Total Liabilities	201.6M	256.5M	339.8M	108.9M	250.3M	7.2M	76.3M	1.8M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	114.3M	0.0	28.9M
Common Stock	56K	53K	52K	44K	1K	2K	1K	1K
Additional Paid-In Capital	1.1B	950.7M	874.3M	523.9M	8.6M	1.4M	308K	0.0
Retained Earnings	-725.8M	-496.8M	-389.5M	-318.8M	-130.1M	-65.1M	-33M	-15.1M
Accumulated Other Comprehensive Income/Loss	843K	848K	547K	-221K	-20K	0.0	0.0	0.0
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	139K
Total Stockholders' Equity	402.4M	454.8M	485.4M	205M	-121.5M	50.5M	-32.7M	14M
Total Equity	402.4M	454.8M	485.4M	205M	-121.5M	50.5M	-32.7M	14M
SUMMARY
Total Liabilities & Equity	604M	711.3M	825.1M	313.8M	128.8M	57.7M	43.6M	15.8M
Total Investments	442.4M	520M	334.6M	190.7M	73.8M	199K	0.0	0.0
Total Debt	96.3M	54.1M	97.6M	88.1M	0.0	0.0	0.0	0.0
Net Debt	16M	-51.6M	-297M	24M	-30.8M	-46.6M	-34.6M	-14.5M
Shares Outstanding	55,398,148	55,398,148	55,398,148	55,398,148	55,398,148	55,398,148	55,398,148	55,398,148

SEC Filings

ACLX - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	April 28, 2026	April 28, 2026	2026	View Filing
10-K/A 10-K/A 2025 FY (Amended) FY	April 24, 2026	December 31, 2025	2025	View Filing
10-K 10-K 2025 FY FY	February 26, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 23, 2026	February 22, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 08, 2025	December 06, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 05, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 05, 2025	November 05, 2025	2025	View Filing
8-K 8-K 2025 N/A	August 07, 2025	August 07, 2025	2025	View Filing
10-Q 10-Q 2025 Q2 Q2	August 07, 2025	June 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	May 28, 2025	May 28, 2025	2025	View Filing

Showing 1 to 10 of 75 filings

Related Guides

Blog Categories

Continue your ACLX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.